Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Archives of General Psychiatry

• Publication date

  1986-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHPSYC.1986.01800100072010PMID 3753162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of the noradrenaline neurotoxin DSP 4 on monoamine neurons and their transmitter turnover in rat CNS

  2005cited by this paper
• Down-regulation of central dopamine receptors in schizophrenia.

  1985cited by this paper
• Are there state-dependent markers in schizophrenia?

  1985cited by this paper
• Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopathological variables.

  1985cited by this paper
• Liquid chromatographic assay for CSF catecholamines using electrochemical detection.

  1984cited by this paper
• Spinal fluid monoamine metabolites and anti-cytomegalovirus antibodies and brain scan evaluation in schizophrenia.

  1984cited by this paper
• CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.

  1984cited by this paper
• Chaotic behavior in dopamine neurodynamics.

  1984cited by this paper
• Determination of conjugated dopamine in cerebrospinal fluid from humans and non-human primates with high performance liquid chromatography using electrochemical detection.

  1984cited by this paper
• Positive and negative symptoms in schizophrenia.

  1984cited by this paper
• Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients.

  1983cited by this paper
• Postnatal development of aminergic projections to frontal cortex: Effects of cortical lesions

  1983cited by this paper
• Lateral ventricular size and drug-induced Parkinsonism.

  1983cited by this paper
• Computed tomographic scans in patients with schizophrenia, schizoaffective, and bipolar affective disorder.

  1983cited by this paper
• Variability and the dopamine hypothesis of schizophrenia.

  1983cited by this paper
• Narcolepsy: biogenic amine deficits in an animal model.

  1983cited by this paper
• Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy.

  1983cited by this paper
• Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection.

  1983cited by this paper
• Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia

  1983cited by this paper
• Clinical correlates of sulcal widening in chronic schizophrenia.

  1983cited by this paper
• Ventricular enlargement in teenage patients with schizophrenia spectrum disorder.

  1983cited by this paper
• Growth Hormone Responses to Apomorphine HCl in Schizophrenic Patients on Drug Holidays and at Relapse

  1983cited by this paper
• d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.

  1982cited by this paper
• Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms.

  1982cited by this paper
• Increased brain dopamine and dopamine receptors in schizophrenia.

  1982cited by this paper
• Ex uno multi: subtyping the schizophrenic syndrome.

  1982cited by this paper
• Hormones, dopamine receptors and schizophrenia.

  1981cited by this paper
• Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.

  1981cited by this paper
• CSF monoamine metabolites in depression and schizophrenia.

  1980cited by this paper
• Positive and Negative Schizophrenic Symptoms and the Role of Dopamine

  1980cited by this paper
• Molecular pathology of schizophrenia: more than one disease process?

  1980cited by this paper
• Positive and Negative Schizophrenic Symptoms and the Role of Dopamine

  1980cited by this paper
• Cerebral ventricular size and neuropsychological impairment in young chronic schizophrenics. Measurement by the standardized Luria-Nebraska Neuropsychological Battery.

  1980cited by this paper
• Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment.

  1980cited by this paper
• Structural abnormalities in the cerebral cortex of chronic schizophrenic patients.

  1979cited by this paper
• The intracortical distribution of norepinephrine, dopamine and serotonin in the cerebral cortex of the cat.

  1979cited by this paper
• Sulcal prominence in young chronic schizophrenic patients: CT scan findings associated with impairment on neuropsychological tests.

  1979cited by this paper
• Evidence of Brain Dopamine Deficiency in Schizophrenia

  1979cited by this paper
• Methylazoxymethanol treatment of fetal rats results in abnormally dense noradrenergic innervation of neocortex.

  1979cited by this paper
• Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: Studies in psychiatric patients

  1979cited by this paper
• Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings

  1979cited by this paper
• Histological and neurochemical effects of fetal treatment with methylazoxymethanol on rat neocortex in adulthood.

  1979cited by this paper
• Lateral cerebral ventricular enlargement in chronic schizophrenia.

  1979cited by this paper
• CSF acid monoamine metabolites in psychotic syndromes: what might they signify?

  1978cited by this paper
• CSF acid monoamine metabolites in psychotic syndromes: what might they signify?

  1978cited by this paper
• Dopamine and norepinephrine innervated cells in the rat prefrontal cortex: pharmacological differentiation using microiontophoretic techniques.

  1976cited by this paper
• Cerebral ventricular size and cognitive impairment in chronic schizophrenia.

  1976cited by this paper
• Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.

  1976cited by this paper
• CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients.

  1976cited by this paper
• IMPORTANCE OF DOPAMINE METABOLISM FOR CLINICAL EFFECTS AND SIDE-EFFECTS OF NEUROLEPTICS

  1976cited by this paper
• Cerebrospinal fluid amine metabolites in acute schizophrenia.

  1975cited by this paper
• Neuroleptics, catecholamines, and psychoses: a study of their interrelations.

  1975cited by this paper
• The origin of the dopamine nerve terminals in limbic and frontal cortex. Evidence for meso-cortico dopamine neurons.

  1974cited by this paper
• Flexible System for the Diagnosis of Schizophrenia: Report from the WHO International Pilot Study of Schizophrenia

  1973cited by this paper
• Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.

  1973cited by this paper
• 5-Hydroxyindoleacetic acid (5 HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines

  1973cited by this paper
• Dopaminergic Terminals in the Rat Cortex

  1973cited by this paper
• Methods for reliable longitudinal observation of behavior.

  1963cited by this paper
• Methods for Reliable Longitudinal Observation of Behavior: Development of a Method for Systematic Observation of Emotional Behavior on Psychiatric Wards

  1963cited by this paper
• CASE HISTORY DATA AND PROGNOSIS IN SCHIZOPHRENIA

  1953cited by this paper

• A journey across dopamine Metabolism: A rotational study of DOPAC.

  2022cites this paper
• Cardiovascular factors are related to dopamine integrity and cognition in aging

  2019cites this paper
• CIRCUIT DYNAMICS UNDERLYING CONTROL OF DOPAMINE NEURON ACTIVITY BY THE NUCLEUS REUNIENS OF THE MIDLINE THALAMUS

  2017cites this paper
• ANALYSIS OF NEUROTRANSMITTERS, NEUROSTEROIDS AND THEIR METABOLITES IN BIOLOGICAL SAMPLES

  2015cites this paper
• Prefrontal dysfunction and a monkey model of schizophrenia

  2015cites this paper
• Determination of Serotonin and Dopamine Metabolites in Human Brain Microdialysis and Cerebrospinal Fluid Samples by UPLC-MS/MS: Discovery of Intact Glucuronide and Sulfate Conjugates

  2013cites this paper
• Schizophrenia-Like Features in Transgenic Mice Overexpressing Human HO-1 in the Astrocytic Compartment

  2012cites this paper
• Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia.

  2012cites this paper
• Pharmacological Models of Psychosis - Amphetamine and Ketamine

  2011cites this paper
• Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance

  2011cites this paper
• Psychotic Continuum

  2010cites this paper
• Dopamine System Dysregulation by the Ventral Subiculum as the Common Pathophysiological Basis for Schizophrenia Psychosis, Psychostimulant Abuse, and Stress

  2010cites this paper
• Ş izofrenide Pozitif/Negatif Ayr

  2010cites this paper
• Extracellular dopamine and norepinephrine in the developing rat prefrontal cortex: transient effects of early partial loss of dopamine.

  2009cites this paper
• Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.

  2009cites this paper
• Anterior Cingulate Neurons Represent Errors and Preparatory Attention within the Same Behavioral Sequence

  2009cites this paper
• Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder.

  2008cites this paper
• Chapter 3 – Chemical Neurotransmission

  2008cites this paper
• Psychiatric disorders and biological dysfunctions: some philosophical questions concerning psychiatry

  2006cites this paper
• Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia

  2005cites this paper
• Studies of dopamlne metabolite levels In drug-free schizophrenic patients Study Subjects Compared with Findings

  2005cites this paper
• Support for limited brain availability of tyrosine in patients with schizophrenia.

  2005cites this paper
• Neurodevelopment and Schizophrenia: Developmental dysregulation of the dopamine system and the pathophysiology of schizophrenia

  2004cites this paper
• Effects of estrogen on brain development and neuroprotection--implications for negative symptoms in schizophrenia.

  2003cites this paper
• Dopamine in Schizophrenia Dysfunctional Information Processing in Basal Ganglia — Thalamocortical Split Circuits

  2002cites this paper
• Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association.

  2002cites this paper
• Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation

  2001cites this paper
• The Effect of Olanzapine Treatment on Monoamine Metabolite Concentrations in the Cerebrospinal Fluid of Schizophrenic Patients

  2001cites this paper
• Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities.

  2001cites this paper
• Gating of information flow within the limbic system and the pathophysiology of schizophrenia.

  2000cites this paper
• Clozapine- and Olanzapine-induced Fos Expression in the Rat Medial Prefrontal Cortex is Mediated by β-Adrenoceptors

  2000cites this paper
• Haloperidol effect on intracellular signals system coupled to alpha1-adrenergic receptor in rat cerebral frontal cortex.

  1999cites this paper
• Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia.

  1999cites this paper
• Genetic antecedents of dopamine dysfunction in schizophrenia.

  1999cites this paper
• Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters.

  1998cites this paper
• Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease.

  1998cites this paper
• TaqI polymorphic sites at the human dopamine β‐hydroxylase gene possibly associated with biochemical alterations of the catecholamine pathway in schizophrenia

  1998cites this paper
• The phencyclidine model of schizophrenia : dysregulation of brain dopamine systems induced by NMDA receptor antagonists

  1998cites this paper
• Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment Response

  1998cites this paper
• Effects of antipsychotics, vitamin E, and MK-801 on dopamine dynamics in the rat brain following discontinuation of cocaine.

  1998cites this paper
• Construct validity of negative symptoms: an empirical and conceptual review.

  1997cites this paper
• Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.

  1997cites this paper
• Reaktionszeitanalyse bei postakut Schizophrenen mit Hilfe elektrophysiologischer Variablen

  1996cites this paper
• [Analysis of reaction time in post-acute schizophrenia using electrophysiologic variables].

  1996cites this paper
• Slow wave sleep and computed tomographic measures of brain morphology in schizophrenia.

  1996cites this paper
• A study of enzymes involved in catecholamine metabolism in parents of patients with schizophrenia.

  1996cites this paper
• Effects of haloperidol and SCH 23390 on acoustic startle in animals depleted of dopamine as neonates: implications for neuropsychiatric syndromes

  1996cites this paper
• [Schizophrenia and neural transmission: an excess of analogical treatment?].

  1996cites this paper
• Basic Neurophysiology of Antipsychotic Drug Action

  1996cites this paper
• Dopamine Turnover in Schizophrenia Before and after Haloperidol Withdrawal

  1996cites this paper
• Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement.

  1995cites this paper
• Biochemical Heterogeneity in Schizophrenia: Implications and Research Strategies of the State Dependency Model

  1995cites this paper
• Low concentrations of serum tyrosine in neuroleptic-free schizophrenics with an early onset.

  1995cites this paper
• Association of polymorphic VNTR region in the first intron of the human TH gene with disturbances of the catecholamine pathway in schizophrenia

  1995cites this paper
• Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected].

  1995cites this paper
• Dopamine agonists in schizophrenia: a review.

  1995cites this paper
• Biochemische Hypothesen zur Negativ-Symptomatik der Schizophrenie

  1994cites this paper
• Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.

  1994cites this paper
• Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.

  1994cites this paper
• Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik

  1994cites this paper
• CSF dopamine beta-hydroxylase in schizophrenia: associations with premorbid functioning and brain computerized tomography scan measures.

  1994cites this paper
• Quantitative Untersuchungen zur Informationsverarbeitung bei Patienten mit schizophrener Minussymptomatik

  1994cites this paper
• Childhood-onset schizophrenia: timely neurobiological research.

  1994cites this paper
• Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review.

  1994cites this paper
• Free radical mechanisms in schizophrenia and tardive dyskinesia.

  1994cites this paper
• L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables.

  1994cites this paper
• Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.

  1994cites this paper
• Serum homovanillic acid levels in schizophrenic patients and normal control subjects.

  1993cites this paper
• Sensitivity to subjective effects of cocaine in drug abusers: relationship to cerebral ventricle size.

  1993cites this paper
• Subjective awareness of abnormal involuntary movements in schizophrenia.

  1993cites this paper
• A meta-analysis of homovanillic acid concentrations in schizophrenia.

  1993cites this paper
• CONCENTRATIONS OF HOMOVANILLIC ACID AND GONADAL HORMONES IN THE SERUM OF MALE SCHIZOPHRENIC PATIENTS

  1993cites this paper
• Late-onset schizophrenia: relationship to awareness of abnormal involuntary movements and tobacco addiction.

  1993cites this paper
• Dopamine autoreceptor agonists in the treatment of schizophrenic disorders.

  1993cites this paper
• Striatal dopamine in reward and attention: a system for understanding the symptomatology of acute schizophrenia and mania.

  1993cites this paper
• An association between increased concentrations of cerebrospinal fluid dopamine sulfate and higher negative symptom scores in patients with schizophrenia and schizoaffective disorder.

  1993cites this paper
• Dopamine in schizophrenia

  1992cites this paper
• Schizophrenia and the D1 receptor: Focus on negative symptoms

  1992cites this paper
• The relationship of structural brain imaging parameters to antipsychotic treatment response: a review.

  1992cites this paper
• The Dopamine Hypothesis and Neurophysiology Concepts in Schizophrenia

  1992cites this paper
• The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia.

  1992cites this paper
• Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects.

  1992cites this paper
• "Positive" and "negative" movement disorders in schizophrenia.

  1992cites this paper
• Advances in Neuroscience and Schizophrenia

  1992cites this paper
• Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression*

  1992cites this paper
• Electrodermal Orienting Response and Central Nervous System: Dopamine and Serotonin Activity in Schizophrenia

  1992cites this paper
• Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.

  1992cites this paper
• Sensory gating in rats depleted of dopamine as neonates: potential relevance to findings in schizophrenic patients.

  1992cites this paper
• A faulty negative feedback control underlies the schizophrenic syndrome?

  1991cites this paper
• "Down regulation" of 5-HT2 receptors: possible role of melatonin and significance for negative schizophrenia.

  1991cites this paper
• Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia.

  1991cites this paper
• Neuroradiological covariates of drug-induced parkinsonism and tardive dyskinesia in schizophrenia.

  1991cites this paper
• Thyroid releasing hormone test in schizophrenic patients with post-psychotic depression.

  1991cites this paper
• The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis

  1991cites this paper
• Melatonin as a mediator of atypical antipsychotic drug effects.

  1991cites this paper
• The relationship of tardive dyskinesia to positive schizophrenia.

  1991cites this paper
• Electroencephalographic sleep and cerebral morphology in functional psychoses: a preliminary study with computed tomography.

  1991cites this paper
• Experimental models of schizophrenia.

  1991cites this paper
• The relationship of pineal calcification to cortical atrophy in schizophrenia.

  1991cites this paper
• Dopamine and norepinephrine activity in schizophrenia. An integrative perspective.

  1991cites this paper